Trial Profile

A phase 2 pilot study to assess daclizumab to improves immune responses induced by rindopepimut, given in combination with temozolomide

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rindopepimut (Primary) ; Daclizumab; Temozolomide
Indications Glioblastoma
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

09 Jun 2009 New trial record.
31 May 2009 Preliminary data were presented in a poster session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Pfizer media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com